Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates protective immunity against rabies virus in mice, highlighting safety and immune response benefits.
Generating recombinant viruses lacking an essential gene for producing infective viral particles represents a promising approach to developing safer live viral vaccines. The envelope-spikes glycoprotein (G) of rabies virus (RABV) plays a critical role in mediating viral adsorption and entry into host cells, making it a key factor influencing its pathogenicity. Herein, we focused on constructing a replication-deficient rabies virus (RABV) with a specific G gene deletion (rSRV9-△G-eGFP). This engineered virus is incapable of forming plaques in cells unless supplemented externally with the G protein, confirming its status as a single-cycle virus producing non-infectious progeny. Despite this restriction, rSRV9-ΔG-eGFP efficiently initiated host immune activation following immunization. Notably, vaccination induced pronounced recruitment and activation of antigen-presenting cells, as well as enhanced T and B lymphocyte responses, highlighting a strong cellular immune component that distinguishes this platform from traditional inactivated rabies vaccines. Consistent with protective immunity, rSRV9-ΔG-eGFP elicited virus-neutralizing antibody titers exceeding the accepted protective threshold of 0.5 IU/mL and conferred protection against lethal RABV challenge. Together, these findings support rSRV9-ΔG-eGFP as a promising replication-deficient rabies vaccine candidate and suggest its potential utility as a viral vector platform for future vaccine development. • A replication-deficient rabies virus (rSRV9-△G-eGFP) was engineered by deleting the G gene, rendering the virus incapable of producing infectious viral particles while still being able to replicate and elicit immune responses. • Immunization with rSRV9-△G-eGFP elicited neutralizing antibodies exceeding 0.5 IU/mL and protected mice from rabies virus challenge. • The recombinant virus platform exhibits good safety.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: